Pancreatic Cancer Research

ResearcherSun Yat-sen UniversityNo recent work listed

Yingxue Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4788-8655, 0009-0007-5198-6358; OpenAlex author ID A5102012757. Sources: OpenAlex.

Their work

Papers
10 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
45
Papers, trials and grants by year

2015: 3 papers · 2016: 2 papers · 2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: 1 paper

Papers 10

  1. Corrigendum to "Long non-coding RNA LOC389641 promotes progression of pancreatic ductal adenocarcinoma and increases cell invasion by regulating E-cadherin in … Co-author DOI 10.1016/j.canlet.2022.215859↗
  2. Author Correction: Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Co-author DOI 10.1038/s41591-020-0947-8↗
  3. Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Co-author DOI 10.1038/s41591-019-0368-8↗
  4. FEZF1-AS1/miR-107/ZNF312B axis facilitates progression and Warburg effect in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41419-017-0052-1↗
  5. Endogenous miRNA Sponge LincRNA-ROR promotes proliferation, invasion and stem cell-like phenotype of pancreatic cancer cells. Co-author DOI 10.1038/cddiscovery.2017.4↗
  6. The long non-coding RNA HOTAIR affects the radiosensitivity of pancreatic ductal adenocarcinoma by regulating the expression of Wnt inhibitory factor 1. Co-author DOI 10.1007/s13277-015-4234-0↗
  7. Long non-coding RNA LOC389641 promotes progression of pancreatic ductal adenocarcinoma and increases cell invasion by regulating E-cadherin in a TNFRSF10A-rela… Co-author DOI 10.1016/j.canlet.2015.12.010↗
  8. High expression of AFAP1-AS1 is associated with poor survival and short-term recurrence in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12967-015-0490-4↗
  9. Expression profile of long non-coding RNAs in pancreatic cancer and their clinical significance as biomarkers. Co-author DOI 10.18632/oncotarget.5533↗
  10. Association between E-cadherin (CDH1) polymorphisms and pancreatic cancer risk in Han Chinese population. First author PMID 26191293↗

Closest collaborators

The 25 strongest of 45 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shangyou Zheng · 7 shared papers, 2015–2022 · strength 0.44
  2. Xiaohui Zhao · 6 shared papers, 2015–2022 · strength 0.40
  3. Yimin Liu · 6 shared papers, 2015–2022 · strength 0.40
  4. Quanbo Zhou · 6 shared papers, 2015–2022 · strength 0.39
  5. Huilin Ye · 5 shared papers, 2015–2022 · strength 0.34
  6. Rufu Chen · 6 shared papers, 2015–2018 · strength 0.32
  7. Wenchao Gao · 5 shared papers, 2015–2022 · strength 0.31
  8. Wenzhu Li · 4 shared papers, 2016–2022 · strength 0.29
  9. Zhiqiang Fu · 5 shared papers, 2015–2018 · strength 0.27
  10. Zhihua Li · 4 shared papers, 2015–2022 · strength 0.27
  11. Yuming Luo · 3 shared papers, 2016–2022 · strength 0.23
  12. Huimou Chen · 3 shared papers, 2016–2022 · strength 0.22
  13. Guolin Li · 3 shared papers, 2016–2018 · strength 0.18
  14. Langping Tan · 2 shared papers, 2016–2022 · strength 0.17
  15. Bjoern Papke · 2 shared papers, 2019–2020 · strength 0.14
  16. Emanuel F. Petricoin · 2 shared papers, 2019–2020 · strength 0.14
  17. Nina V. Chaika · 2 shared papers, 2019–2020 · strength 0.14
  18. Yan Liang · 2 shared papers, 2019–2020 · strength 0.14
  19. J. Nathaniel Diehl · 2 shared papers, 2019–2020 · strength 0.14
  20. Venugopal Gunda · 2 shared papers, 2019–2020 · strength 0.14
  21. Mariaelena Pierobon · 2 shared papers, 2019–2020 · strength 0.14
  22. Daniel Zeitouni · 2 shared papers, 2019–2020 · strength 0.14
  23. Haoqiang Ying · 2 shared papers, 2019–2020 · strength 0.14
  24. Kirsten L. Bryant · 2 shared papers, 2019–2020 · strength 0.14
  25. Adrienne D. Cox · 2 shared papers, 2019–2020 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.